Use of glp-1r / gipr dual agonist in the preparation of an animal drug

CN122396499APending Publication Date: 2026-07-14HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
Filing Date
2024-11-21
Publication Date
2026-07-14

AI Technical Summary

Technical Problem

There is a lack of GLP-1R agonist drugs for pet obesity and hyperglycemia in the prior art, and there is no GLP-1R/GIPR dual-target agonist drugs suitable for pets, resulting in poor treatment of pet diseases.

Method used

A long-acting GLP-1R/GIPR dual-target agonist compound has excellent dual-agonism activity, showing significant lowering of glycemic and weight loss effects in dogs, cats, rabbits, pigs, alpacas, horses, sheep and cattle, and has low side effects.

Benefits of technology

The compound exhibits stronger hypoglycemia, more significant weight loss effects in a variety of genus animals, and has lower side effects, including gastrointestinal reactions and cardiac safety risks, and can adopt a shorter titration strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122396499A_ABST
    Figure CN122396499A_ABST
Patent Text Reader

Abstract

Use of GLP-1R / GIPR dual-target agonist compounds for the preparation of a medicament for the prevention or treatment of a disease in a non-primate and non-rodent animal.
Need to check novelty before this filing date? Find Prior Art